The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family Chair in Pediatric IBD Professor of Pediatrics University of Pennsylvania School of Medicine Director, Center for Pediatric IBD The Children's Hospital of Philadelphia Are we changing the Natural History by using clinical symptoms as our end-point?? Treat the patient not the lab tests Intestinal Resection in Different Cohorts 60 % of Patients P = 0.81 No change in operative rates 40 20 0 0 1978-82 1983-87 12 24 36 48 Months After Diagnosis 1988-92 60 1993-97 1998-2002 6MP was standard therapy at this time Cosnes J, et al. Gut. 2005;54:237. Crohn’s Disease Progression on “Conventional” Therapy in Children: 1988-2002 Inflammatory 34% at 5 yrs Stricturing Penetrating Vernier-Massouille et al. Gastroenterology 2008;135:1106 3 Shifting CD Therapeutic Goals PREVIOUS GOALS Induce & maintain clinical remission Improve quality of life Minimize drug toxicity Optimize surgical outcomes ADDED GOALS Heal the mucosa Modify the natural history of disease Prevent complications!! Does good symptom control mean good disease control? Cannabis induces a clinical response in patients with CD • 21 patients randomized to placebo vs. cannabis with THC • Significant “response” in CDAI in THC group (90% vs. 40%) at 8 weeks • NO change in HCT or CRP • Conclusion: getting high lowers your CDAI. Naftali, et al. CGH 2013 The CDAI- Subjective and Non-Specific • Higher CDAIs in IBS patients • Pain scores higher (p=0.1) Mean CDAI Score • 91 consecutive patients with CD or IBS 183 157 Lahiff C. et al. Aliment Pharmacol Ther. 2013; 37(8):786- 94 Crohn’s Disease Activity Index ( CDAI ) Relationship Between Clinical Symptoms and Endoscopic Indices at Presentation of Acute CD 600 500 400 300 200 100 R=0.13; NS 0 0 5 10 15 20 25 30 35 Crohn’s Disease Endoscopic Index of Severity (CDEIS) Modigliani R et al. Gastroenterology. 1990;98:811. Lack of Correlation Between Endoscopy and Clinical Symptoms (Which One is Really Measuring the Disease?) • Endoscopy is not a biomarker, endoscopy is physical (visual) examination of the ileum and colon – Analogies • Psoriasis – physical (visual) examination showing presence and severity of typical skin lesions • Rheumatoid arthritis – physical examination showing swollen and tender joints + biomarkers • Clinical symptoms are a surrogate for endoscopy findings, not the other way around MR Enterography • 50 CD patients • Ileocolonoscopy and MRE • Strong correlation between CDEIS and wall thickness, ulceration, enhancement, edema • R=0.82 for MRE score and CDEIS • MRE highly accurate for assessment of active disease Rimola et al Gut 2009 Treat-to-Target IBD • This strategy requires a new treatment target. – Clinical remission – Control of inflammation (mucosal healing) Deep Remission Treat-to-Target – This approach is taken with other chronic, progressive diseases where there are clearly defined treatment targets • Hypertension, Diabetes and Rheumatoid Arthritis – No longer sufficient to aim to treat to symptom control Deep Remission • Goals – Prevention of bowel damage – Reduction of long-term disability – Maintenance of good quality of life Deep Remission after 1 year of treatment for UC is predictive of a decreased rate of colectomy Froslie KF, et al. Gastro 2007 EXTEND Study Time to Loss of Response at week 52 with and without Deep Remission (DR) at week 12 Colombel JF, et al. Clin Gastro Hep; 2014 (in press) EXTEND Study Quality of life and Productivity at week 52 with and without Deep Remission (DR) at week 12 Colombel JF, et al. Clin Gastro Hep ; 2014 (in press) Meaningful Response: The clinician’s perspective This is not the only reason for a colonoscopy. Spryliving.com March 2012 http://spryliving.com/articles/8-ways-to-a-hasslefree-colonoscopy/